User login
Telemedicine on Trial
A new study questioning the efficacy of telemedicine in reducing length of stay (LOS) and improving patient care in the ICU is further proof that remote patient care only works when there is a strong support structure behind it, according to a former SHM president.
“The studies in the past have not shown that just because you have an intensivist available that you are going to get a lot of bang for the buck. You need to have a real process. … If you don’t implement something properly, you can’t expect to get results,” says Mary Jo Gorman, MD, MBA, FHM, former SHM president and CEO of St. Louis-based Advanced ICU Care, which provides intensivists to community hospitals using telemedicine.
Investigators at the University of Texas Health Science Center at Houston reviewed some 4,000 patients in six ICUs at five hospitals in a large U.S. healthcare system by measuring outcomes before and after implementation of a “tele-ICU” from 2003 to 2006. No statistically significant impacts were seen in mortality rates, complications, or LOS (JAMA. 2009;302[24]:2671-2678). Conversely, an accompanying editorial in the Journal of the American Medical Association argued that “tele-ICU is a potentially valuable change in ICU care, but its complexity means that ‘tele-ICU improves care’ is not a testable hypothesis.”
The use of off-site intensivists to monitor patients has been used in recent years to address the shortage of ICU physicians. Still, the study team argues that “there are few data in the peer-reviewed literature evaluating its effect on morbidity and mortality.”
Dr. Gorman suggests that HM groups looking to partner with telemedicine providers consider the importance of:
- Following the costs and intricacies of technical implementation;
- Getting local physician buy-in;
- Creating a multidisciplinary approach that includes nurses and pharmacists; and
- Putting periodic reviews in place to measure quality metrics.
“The tool is not the problem,” Dr. Gorman adds. “It’s how do you implement the tool.”
A new study questioning the efficacy of telemedicine in reducing length of stay (LOS) and improving patient care in the ICU is further proof that remote patient care only works when there is a strong support structure behind it, according to a former SHM president.
“The studies in the past have not shown that just because you have an intensivist available that you are going to get a lot of bang for the buck. You need to have a real process. … If you don’t implement something properly, you can’t expect to get results,” says Mary Jo Gorman, MD, MBA, FHM, former SHM president and CEO of St. Louis-based Advanced ICU Care, which provides intensivists to community hospitals using telemedicine.
Investigators at the University of Texas Health Science Center at Houston reviewed some 4,000 patients in six ICUs at five hospitals in a large U.S. healthcare system by measuring outcomes before and after implementation of a “tele-ICU” from 2003 to 2006. No statistically significant impacts were seen in mortality rates, complications, or LOS (JAMA. 2009;302[24]:2671-2678). Conversely, an accompanying editorial in the Journal of the American Medical Association argued that “tele-ICU is a potentially valuable change in ICU care, but its complexity means that ‘tele-ICU improves care’ is not a testable hypothesis.”
The use of off-site intensivists to monitor patients has been used in recent years to address the shortage of ICU physicians. Still, the study team argues that “there are few data in the peer-reviewed literature evaluating its effect on morbidity and mortality.”
Dr. Gorman suggests that HM groups looking to partner with telemedicine providers consider the importance of:
- Following the costs and intricacies of technical implementation;
- Getting local physician buy-in;
- Creating a multidisciplinary approach that includes nurses and pharmacists; and
- Putting periodic reviews in place to measure quality metrics.
“The tool is not the problem,” Dr. Gorman adds. “It’s how do you implement the tool.”
A new study questioning the efficacy of telemedicine in reducing length of stay (LOS) and improving patient care in the ICU is further proof that remote patient care only works when there is a strong support structure behind it, according to a former SHM president.
“The studies in the past have not shown that just because you have an intensivist available that you are going to get a lot of bang for the buck. You need to have a real process. … If you don’t implement something properly, you can’t expect to get results,” says Mary Jo Gorman, MD, MBA, FHM, former SHM president and CEO of St. Louis-based Advanced ICU Care, which provides intensivists to community hospitals using telemedicine.
Investigators at the University of Texas Health Science Center at Houston reviewed some 4,000 patients in six ICUs at five hospitals in a large U.S. healthcare system by measuring outcomes before and after implementation of a “tele-ICU” from 2003 to 2006. No statistically significant impacts were seen in mortality rates, complications, or LOS (JAMA. 2009;302[24]:2671-2678). Conversely, an accompanying editorial in the Journal of the American Medical Association argued that “tele-ICU is a potentially valuable change in ICU care, but its complexity means that ‘tele-ICU improves care’ is not a testable hypothesis.”
The use of off-site intensivists to monitor patients has been used in recent years to address the shortage of ICU physicians. Still, the study team argues that “there are few data in the peer-reviewed literature evaluating its effect on morbidity and mortality.”
Dr. Gorman suggests that HM groups looking to partner with telemedicine providers consider the importance of:
- Following the costs and intricacies of technical implementation;
- Getting local physician buy-in;
- Creating a multidisciplinary approach that includes nurses and pharmacists; and
- Putting periodic reviews in place to measure quality metrics.
“The tool is not the problem,” Dr. Gorman adds. “It’s how do you implement the tool.”
In the Literature: The Latest Research You Need to Know
Clinical question: What are the efficacy and safety of a simplified “1+1” pain protocol using 1-mg IV hydromorphone followed by an optional repeat dose at patient request 15 minutes later in patients with acute pain?
Background: ED patients receive inadequate treatment of pain. Previously studied protocols utilized weight-based dosing, complex pain scales, and frequent nurse contact to assess and treat pain, making them less useful in a busy ED. A 2-mg single dose hydromorphone protocol provided pain relief, but was associated with oxygen desaturation.
Study design: Prospective interventional cohort study.
Setting: Adult, urban, academic ED with an annual census of approximately 89,000.
Synopsis: Participants included 223 ED patients ages 21 to 64 years old presenting with acute pain (<7 days duration) of sufficient severity to warrant use of IV opioids. Notable exclusion criteria included use of opioids within the past seven days, history of chronic pain, room air saturation <95%, systolic blood pressure <90 mm/Hg, or contraindication to hydromorphone; thus, findings are applicable to a limited set of ED patients presenting with acute pain. The hydromorphone protocol achieved patient expectations of pain relief (defined by decision to forgo additional opioid medication) in 77% of patients within 15 minutes and 96% of patients within one hour. 5% of patients dropped their oxygen saturations to <95%, but all increased promptly with 4L nasal cannula. Only 1% of patients dropped their respiratory rate to <12 breaths/minute and systolic blood pressure to <100 mm/Hg; none required naloxone use.
Limitations include lack of comparison group, unblinded design, and findings from a single urban center (in which participants were 60% Hispanic, 29% black, and 65% female). While there were no serious adverse events, the sample size is not large enough to identify rare events.
Bottom line: In nonelderly adult ED patients without a history of chronic pain or recent opioids, a pain protocol of 1-mg IV hydromorphone repeated in 15 minutes if needed is effective and safe, assuming typical ED monitoring for hypoxia and respiratory depression.
Citation: Chang AK, Bijur PE, Campbell CM, Murphy MK, Gallagher EJ. Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the “1+1” protocol. Ann Emerg Med. 2009;54(2):221-225.
Reviewed for TH eWire by Bhaskar Arora, MD, Thomas Barrett, MD, MCR, FHM, Honora Englander, MD, Stephanie Halvorson, MD, Alan J. Hunter, MD, David Kagen, MD, Blake Lesselroth, MD, MBI, Portland Veterans Affairs Medical Center and Division of Hospital Medicine, Oregon Health & Science University
For more HM-related literature reviews, visit our Web site.
Clinical question: What are the efficacy and safety of a simplified “1+1” pain protocol using 1-mg IV hydromorphone followed by an optional repeat dose at patient request 15 minutes later in patients with acute pain?
Background: ED patients receive inadequate treatment of pain. Previously studied protocols utilized weight-based dosing, complex pain scales, and frequent nurse contact to assess and treat pain, making them less useful in a busy ED. A 2-mg single dose hydromorphone protocol provided pain relief, but was associated with oxygen desaturation.
Study design: Prospective interventional cohort study.
Setting: Adult, urban, academic ED with an annual census of approximately 89,000.
Synopsis: Participants included 223 ED patients ages 21 to 64 years old presenting with acute pain (<7 days duration) of sufficient severity to warrant use of IV opioids. Notable exclusion criteria included use of opioids within the past seven days, history of chronic pain, room air saturation <95%, systolic blood pressure <90 mm/Hg, or contraindication to hydromorphone; thus, findings are applicable to a limited set of ED patients presenting with acute pain. The hydromorphone protocol achieved patient expectations of pain relief (defined by decision to forgo additional opioid medication) in 77% of patients within 15 minutes and 96% of patients within one hour. 5% of patients dropped their oxygen saturations to <95%, but all increased promptly with 4L nasal cannula. Only 1% of patients dropped their respiratory rate to <12 breaths/minute and systolic blood pressure to <100 mm/Hg; none required naloxone use.
Limitations include lack of comparison group, unblinded design, and findings from a single urban center (in which participants were 60% Hispanic, 29% black, and 65% female). While there were no serious adverse events, the sample size is not large enough to identify rare events.
Bottom line: In nonelderly adult ED patients without a history of chronic pain or recent opioids, a pain protocol of 1-mg IV hydromorphone repeated in 15 minutes if needed is effective and safe, assuming typical ED monitoring for hypoxia and respiratory depression.
Citation: Chang AK, Bijur PE, Campbell CM, Murphy MK, Gallagher EJ. Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the “1+1” protocol. Ann Emerg Med. 2009;54(2):221-225.
Reviewed for TH eWire by Bhaskar Arora, MD, Thomas Barrett, MD, MCR, FHM, Honora Englander, MD, Stephanie Halvorson, MD, Alan J. Hunter, MD, David Kagen, MD, Blake Lesselroth, MD, MBI, Portland Veterans Affairs Medical Center and Division of Hospital Medicine, Oregon Health & Science University
For more HM-related literature reviews, visit our Web site.
Clinical question: What are the efficacy and safety of a simplified “1+1” pain protocol using 1-mg IV hydromorphone followed by an optional repeat dose at patient request 15 minutes later in patients with acute pain?
Background: ED patients receive inadequate treatment of pain. Previously studied protocols utilized weight-based dosing, complex pain scales, and frequent nurse contact to assess and treat pain, making them less useful in a busy ED. A 2-mg single dose hydromorphone protocol provided pain relief, but was associated with oxygen desaturation.
Study design: Prospective interventional cohort study.
Setting: Adult, urban, academic ED with an annual census of approximately 89,000.
Synopsis: Participants included 223 ED patients ages 21 to 64 years old presenting with acute pain (<7 days duration) of sufficient severity to warrant use of IV opioids. Notable exclusion criteria included use of opioids within the past seven days, history of chronic pain, room air saturation <95%, systolic blood pressure <90 mm/Hg, or contraindication to hydromorphone; thus, findings are applicable to a limited set of ED patients presenting with acute pain. The hydromorphone protocol achieved patient expectations of pain relief (defined by decision to forgo additional opioid medication) in 77% of patients within 15 minutes and 96% of patients within one hour. 5% of patients dropped their oxygen saturations to <95%, but all increased promptly with 4L nasal cannula. Only 1% of patients dropped their respiratory rate to <12 breaths/minute and systolic blood pressure to <100 mm/Hg; none required naloxone use.
Limitations include lack of comparison group, unblinded design, and findings from a single urban center (in which participants were 60% Hispanic, 29% black, and 65% female). While there were no serious adverse events, the sample size is not large enough to identify rare events.
Bottom line: In nonelderly adult ED patients without a history of chronic pain or recent opioids, a pain protocol of 1-mg IV hydromorphone repeated in 15 minutes if needed is effective and safe, assuming typical ED monitoring for hypoxia and respiratory depression.
Citation: Chang AK, Bijur PE, Campbell CM, Murphy MK, Gallagher EJ. Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the “1+1” protocol. Ann Emerg Med. 2009;54(2):221-225.
Reviewed for TH eWire by Bhaskar Arora, MD, Thomas Barrett, MD, MCR, FHM, Honora Englander, MD, Stephanie Halvorson, MD, Alan J. Hunter, MD, David Kagen, MD, Blake Lesselroth, MD, MBI, Portland Veterans Affairs Medical Center and Division of Hospital Medicine, Oregon Health & Science University
For more HM-related literature reviews, visit our Web site.
JOURNAL SCANSummary of Key ArticlesIdentifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
Summary of Key Articles
Identifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information
Faculty/Faculty Disclosure
Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.
A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information
Faculty/Faculty Disclosure
Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.
A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information
Faculty/Faculty Disclosure
Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.
Summary of Key Articles
Identifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
Summary of Key Articles
Identifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
Practical Neuroscience for Primary Care Physicians: Summer 2008
A supplement to Family Practice News and Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.
Practical Bits: Quick and Practical Diagnostic Tools
Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.
Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.
A supplement to Family Practice News and Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.
Practical Bits: Quick and Practical Diagnostic Tools
Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.
Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.
A supplement to Family Practice News and Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.
Practical Bits: Quick and Practical Diagnostic Tools
Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.
Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.
Practical Neuroscience for Primary Care Physicians: Spring 2008
A supplement to Family Practice News and Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.
Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD
Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.
Practical Bits: Quick and Practical Diagnostic Tools
Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.
Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.
A supplement to Family Practice News and Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.
Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD
Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.
Practical Bits: Quick and Practical Diagnostic Tools
Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.
Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.
A supplement to Family Practice News and Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.
Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD
Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.
Practical Bits: Quick and Practical Diagnostic Tools
Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.
Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.
Practical Neuroscience for Primary Care Physicians: Winter 2007
A supplement to Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.
Resources in the Spotlight
Practical Bits: Quick and Practical Diagnostic Tools
Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.
Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.
Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.
Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.
A supplement to Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.
Resources in the Spotlight
Practical Bits: Quick and Practical Diagnostic Tools
Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.
Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.
Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.
Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.
A supplement to Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.
Resources in the Spotlight
Practical Bits: Quick and Practical Diagnostic Tools
Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.
Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.
Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.
Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.
Practical Neuroscience for Primary Care Physicians: Fall 2007
A supplement to Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.
Practical Bits
Quick and Practical Diagnostic Tools
Resources in the Spotlight
Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.
Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.
Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.
A supplement to Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.
Practical Bits
Quick and Practical Diagnostic Tools
Resources in the Spotlight
Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.
Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.
Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.
A supplement to Internal Medicine News.
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.
Practical Bits
Quick and Practical Diagnostic Tools
Resources in the Spotlight
Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.
Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.
Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.
Practical Neuroscience for Primary Care Physicians: Summer 2007
A supplement to Internal Medicine News.
[[{"attributes":{},"fields":{}}]]
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.
Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.
Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.
Resources in the Spotlight
Practical Bits
Quick and Practical Diagnostic Tools
A supplement to Internal Medicine News.
[[{"attributes":{},"fields":{}}]]
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.
Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.
Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.
Resources in the Spotlight
Practical Bits
Quick and Practical Diagnostic Tools
A supplement to Internal Medicine News.
[[{"attributes":{},"fields":{}}]]
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.
Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.
Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.
Resources in the Spotlight
Practical Bits
Quick and Practical Diagnostic Tools
Letter to the Editor
Prado et al.'s1 insightful analysis on a rapid response system failure draws attention to afferent limb system failures of medical emergency teams (METs). The article also serves to highlight several key quality improvement (QI) educational points. The authors demonstrate a thorough grasp of the literature concerning METs. The case description reveals a detailed investigation that is thorough enough to create a timeline of events. I applaud the literature review and construction of a timeline, as these represent the first several steps of a root‐cause analysisbut they are somewhat insufficient. More work can be done here.
Extending their line of inquiry may uncover specific system factors involved in the afferent limb failure. To further the analysis, careful interviews of all involved personnel (including patients, family members, and nurses) may help identify the factors that compromise afferent limbs of METs and thereby make necessary improvements, as in the innovative Josie King Safety Program at Johns Hopkins Hospital (Baltimore, MD). Prado et al.1 are extremely fortunate in that their institution has a monitoring system in place to track MET activations. A more ambitious, though potentially more fruitful project, would be to, examine previous afferent limb failures in an effort to identify systems factors that are more generalizable to other institutions.
The difficulties in obtaining data are 2‐fold: first in gathering the data, and second in extending the data beyond one's own institution. The very nature of QI data, eg, data that are locally obtained and relevant to a particular institution, hinders its generalizability. However, afferent limb failures are real and perhaps ubiquitous.2, 3 The challenge then, is to develop strategies that can improve the functioning of METs (both afferent and efferent limbs) regardless of the institution.
As afferent limbs of METs have been identified as a priority for future attention for the greatest benefit,2, 4 the process of analyzing root‐causes of systems failures seems to be analogous to identifying risk factors for a novel disease. Once identified, the appropriate risk‐factor modifications can be undertaken. Only by careful examination of the data can true, relevant factors be identified. For this reason, I feel that Prado et al.'s1 excellent work should be expanded upon and replicated in other institutions.
Should these types of QI projects become more amenable to extrapolation to other institutions, a predominant reporting format may be needed. The Standards for Quality Improvement Reporting Excellence (SQUIRE) guideline
- Rapid response: a quality improvement conundrum.J Hosp Med.2009;4(4):255–257. , , , .
- Effects of rapid response systems on clinical outcomes: systematic review and meta‐analysis.J Hosp Med.2007;2(6):422–432. , , , , .
- Outreach and early warning systems (EWS) for the prevention of intensive care admission and death of critically ill adult patients on general hospital wards.Cochrane Database Syst Rev2007(3):CD005529. , , , et al.
- Introduction of the medical emergency team (MET) system: a cluster‐randomised controlled trial.Lancet.2005;365(9477):2091–2097. , , , et al.
- Clinicians in quality improvement: a new career pathway in academic medicine.JAMA.2009;301(7):766–768. , .
- SGIM. Quality Portfolio Introduction. Available at: http://www.sgim.org/index.cfm?pageId=846. Accessed September2009.
Prado et al.'s1 insightful analysis on a rapid response system failure draws attention to afferent limb system failures of medical emergency teams (METs). The article also serves to highlight several key quality improvement (QI) educational points. The authors demonstrate a thorough grasp of the literature concerning METs. The case description reveals a detailed investigation that is thorough enough to create a timeline of events. I applaud the literature review and construction of a timeline, as these represent the first several steps of a root‐cause analysisbut they are somewhat insufficient. More work can be done here.
Extending their line of inquiry may uncover specific system factors involved in the afferent limb failure. To further the analysis, careful interviews of all involved personnel (including patients, family members, and nurses) may help identify the factors that compromise afferent limbs of METs and thereby make necessary improvements, as in the innovative Josie King Safety Program at Johns Hopkins Hospital (Baltimore, MD). Prado et al.1 are extremely fortunate in that their institution has a monitoring system in place to track MET activations. A more ambitious, though potentially more fruitful project, would be to, examine previous afferent limb failures in an effort to identify systems factors that are more generalizable to other institutions.
The difficulties in obtaining data are 2‐fold: first in gathering the data, and second in extending the data beyond one's own institution. The very nature of QI data, eg, data that are locally obtained and relevant to a particular institution, hinders its generalizability. However, afferent limb failures are real and perhaps ubiquitous.2, 3 The challenge then, is to develop strategies that can improve the functioning of METs (both afferent and efferent limbs) regardless of the institution.
As afferent limbs of METs have been identified as a priority for future attention for the greatest benefit,2, 4 the process of analyzing root‐causes of systems failures seems to be analogous to identifying risk factors for a novel disease. Once identified, the appropriate risk‐factor modifications can be undertaken. Only by careful examination of the data can true, relevant factors be identified. For this reason, I feel that Prado et al.'s1 excellent work should be expanded upon and replicated in other institutions.
Should these types of QI projects become more amenable to extrapolation to other institutions, a predominant reporting format may be needed. The Standards for Quality Improvement Reporting Excellence (SQUIRE) guideline
Prado et al.'s1 insightful analysis on a rapid response system failure draws attention to afferent limb system failures of medical emergency teams (METs). The article also serves to highlight several key quality improvement (QI) educational points. The authors demonstrate a thorough grasp of the literature concerning METs. The case description reveals a detailed investigation that is thorough enough to create a timeline of events. I applaud the literature review and construction of a timeline, as these represent the first several steps of a root‐cause analysisbut they are somewhat insufficient. More work can be done here.
Extending their line of inquiry may uncover specific system factors involved in the afferent limb failure. To further the analysis, careful interviews of all involved personnel (including patients, family members, and nurses) may help identify the factors that compromise afferent limbs of METs and thereby make necessary improvements, as in the innovative Josie King Safety Program at Johns Hopkins Hospital (Baltimore, MD). Prado et al.1 are extremely fortunate in that their institution has a monitoring system in place to track MET activations. A more ambitious, though potentially more fruitful project, would be to, examine previous afferent limb failures in an effort to identify systems factors that are more generalizable to other institutions.
The difficulties in obtaining data are 2‐fold: first in gathering the data, and second in extending the data beyond one's own institution. The very nature of QI data, eg, data that are locally obtained and relevant to a particular institution, hinders its generalizability. However, afferent limb failures are real and perhaps ubiquitous.2, 3 The challenge then, is to develop strategies that can improve the functioning of METs (both afferent and efferent limbs) regardless of the institution.
As afferent limbs of METs have been identified as a priority for future attention for the greatest benefit,2, 4 the process of analyzing root‐causes of systems failures seems to be analogous to identifying risk factors for a novel disease. Once identified, the appropriate risk‐factor modifications can be undertaken. Only by careful examination of the data can true, relevant factors be identified. For this reason, I feel that Prado et al.'s1 excellent work should be expanded upon and replicated in other institutions.
Should these types of QI projects become more amenable to extrapolation to other institutions, a predominant reporting format may be needed. The Standards for Quality Improvement Reporting Excellence (SQUIRE) guideline
- Rapid response: a quality improvement conundrum.J Hosp Med.2009;4(4):255–257. , , , .
- Effects of rapid response systems on clinical outcomes: systematic review and meta‐analysis.J Hosp Med.2007;2(6):422–432. , , , , .
- Outreach and early warning systems (EWS) for the prevention of intensive care admission and death of critically ill adult patients on general hospital wards.Cochrane Database Syst Rev2007(3):CD005529. , , , et al.
- Introduction of the medical emergency team (MET) system: a cluster‐randomised controlled trial.Lancet.2005;365(9477):2091–2097. , , , et al.
- Clinicians in quality improvement: a new career pathway in academic medicine.JAMA.2009;301(7):766–768. , .
- SGIM. Quality Portfolio Introduction. Available at: http://www.sgim.org/index.cfm?pageId=846. Accessed September2009.
- Rapid response: a quality improvement conundrum.J Hosp Med.2009;4(4):255–257. , , , .
- Effects of rapid response systems on clinical outcomes: systematic review and meta‐analysis.J Hosp Med.2007;2(6):422–432. , , , , .
- Outreach and early warning systems (EWS) for the prevention of intensive care admission and death of critically ill adult patients on general hospital wards.Cochrane Database Syst Rev2007(3):CD005529. , , , et al.
- Introduction of the medical emergency team (MET) system: a cluster‐randomised controlled trial.Lancet.2005;365(9477):2091–2097. , , , et al.
- Clinicians in quality improvement: a new career pathway in academic medicine.JAMA.2009;301(7):766–768. , .
- SGIM. Quality Portfolio Introduction. Available at: http://www.sgim.org/index.cfm?pageId=846. Accessed September2009.
Aching for a Diagnosis
A 23‐year‐old Caucasian man presented to an outpatient clinic with a sore throat and associated subjective fevers. His evaluation included a negative rapid streptococcus test; nevertheless, he was empirically treated with amoxicillin. The following day, he experienced increasing sore throat and presented to the emergency department (ED). He was treated with prednisone and morphine sulfate and discharged home with azithromycin.
Initial considerations in a healthy young man who presents with fever and pharyngitis should focus on common infectious etiologies. Viral illnesses are the most frequent causes of sore throat and fever. These often manifest as mononucleosis‐like illnesses and include Epstein‐Barr virus (EBV) and cytomegalovirus (CMV). In this age group, it is also critical to consider sexually transmitted diseases (STDs) such as gonorrhea, human immunodeficiency virus (HIV), herpes simplex virus, and syphilis. Consideration of streptococcal pharyngitis is important. Since the rapid streptococcal antigen test is neither sensitive nor specific, confirmation of infection should be based on clinical findings and a culture of the pharynx for group A Streptococcus. Other common etiologies of fever and pharyngitis include acute or chronic sinusitis with postnasal drainage. Due to the progressive nature of the sore throat, there should be an evaluation for difficulty swallowing, problems phonating, or neck discomfort, any of which would be concerning for a retropharyngeal abscess. Additional history should be obtained with focus on sexual history, previous STDs, recent sick contacts, and other supporting signs and symptoms of viral illnesses.
Eight days after the initial onset of symptoms, the patient developed acute low back pain. The back pain was midline, severe, and constant around the lumbar spine. There was no saddle anesthesia, bowel or bladder dysfunction, or weakness or numbness in the extremities. He also noted swelling of the left fourth metacarpophalangeal joint and an erythematous rash on his right knee and anterior tibial region of the right leg. He continued to experience subjective fevers, sore throat, and swollen neck glands. Due to the severity and discomfort of symptoms, the patient returned to the ED.
With no history of trauma, the subsequent development of acute low back pain may be related to the patient's sore throat and fever. Monoarticular arthritis with contralateral skin lesions should raise suspicion for a systemic process, particularly infection or a rheumatologic syndrome. Infectious etiologies would include rheumatic fever, endocarditis with septic emboli, and osteomyelitis. Rheumatologic causes, such as ankylosing spondylitis and juvenile rheumatoid arthritis (RA), are also possibilities. The infectious evaluation should include an assessment of a history of intravenous drug use (IVDU) and underlying valvular disorders, which will increase the risk for endocarditis and therefore septic emboli. Acute HIV infection can be seen as early as 1 to 2 weeks postexposure and should be considered as well. Appropriate testing would include both conventional HIV antibody tests and HIV viral load assay. Lastly, in considering the patient's symptoms, obtaining his travel history to identify risk for Lyme disease would also be appropriate.
The patient did not report any further positive findings on review of systems. He did not have any significant past medical history and did not take any chronic medications. He had no sick contacts. He rarely drank alcohol and denied IVDU and sexual activity over the past year. He was previously involved in monogamous relationships with women. His last HIV test, 1 year prior, was negative. He did not have any history of STDs. He was a graduate student in computer science and lived in southern California. He had recently traveled to central California and France for 2 weeks, staying in larger cities. He had not been hiking during that time. His family history was significant for hypertension.
The travel history is provocative for 3 diseases of the reticuloendothelial system with possible systemic manifestations. First, toxoplasmosis, which is endemic in France where rare or raw beef and lamb are frequently consumed. It may present as a mononucleosis‐like illness and rarely as atypical pneumonia. Second, tuberculosis, which is also endemic in France, especially in major cities. Although most commonly a self‐limited respiratory disease, it may disseminate with systemic symptoms. Third, primary coccidioidomycosis, which is prevalent in the central valleys of California. The climate and wind patterns lead to aerosolization of the spores and make this a common respiratory pathogen.
The physical exam should include a detailed evaluation of the eyes for uveitis and iritis, seen in some rheumatologic disorders. A pharyngeal exam with assessment for exudate can support streptococcal pharyngitis or diphtheria. Evaluation for lymphadenopathy, while nonspecific, would be important for streptococcal pharyngitis, rheumatic fever, and juvenile RA. Further characterizing the rash is essential in distinguishing viral exanthems from the fleeting salmon‐colored maculopapular rash of juvenile RA. Assessment for peripheral stigmata of endocarditis should be done. A thorough joint exam should evaluate evidence of inflammatory or infectious joint disease.
On physical exam, he was a thin man who appeared anxious but in no acute distress. His temperature was 36.7C, blood pressure 111/68 mm Hg, heart rate 83 beats/minute, respiratory rate 16 breaths/minute, and oxygen saturation 99% on room air. Erythema was noted in the posterior oropharynx with no tonsillar exudate. There were several subcentimeter, nontender, and mobile lymph nodes in the anterior cervical chain bilaterally. The cardiovascular exam revealed normal sinus rhythm with a 2/6 systolic murmur at the apex, without radiation. His lungs were clear to auscultation. Skin exam revealed 2 blanching erythematous, indurated, and tender lesions on the right pretibial region, 2‐cm and 4‐cm in diameter. Two other similar, but smaller, lesions were noted on the left upper extremity and left ankle. His lumbar spine was slightly tender to touch. A complete joint exam was normal, including the left fourth metacarpophalangeal joint. Neurological exam, including bilateral strength, sensation, reflexes, and gait, was unremarkable.
Younger patients are subject to social‐acceptance bias and can deny sexual activity on initial inquiry. An objective evaluation for STDs with serologic workup should still be pursued. The cervical lymphadenopathy and tonsillar erythema continue to suggest a viral illness. While the systolic murmur may be physiologic, subjective fevers, disseminated cutaneous lesions, and arthritis warrant evaluation for bacterial endocarditis with blood cultures and an echocardiogram.
On exam, there is no evidence of true joint involvement and this decreases the likelihood of rheumatologic conditions, such as ankylosing spondylitis and juvenile RA. However, the skin lesions are suspicious for erythema nodosum (EN), which should prompt a biopsy and an evaluation for infectious etiologies. Serologies should include evaluation of Chlamydia, Mycoplasma, Coccidioides, and Histoplasma. I would also examine the feet carefully for potential transcutaneous inoculation by microorganisms that can produce a rash similar to EN. For instance, penetrating skin trauma can lead to pseudomonal infection. Brucella (from ingesting unpasteurized milk or milk products), Bartonella (from the scratches of feline animals), and Francisella tularensis (from rabbit exposure) can also produce skin lesions that mimic EN. These are best distinguished through a detailed history, concomitant serologic workup, and biopsy. Other noninfectious etiologies of EN can include inflammatory bowel disease, Behcet's, and sarcoidosis; however, the patient does not currently report any symptoms supporting these diagnoses. In addition to the above evaluation, complete blood count with differential, liver function tests, creatinine, and urinalysis should be obtained.
The patient's white blood cell (WBC) count was 12,100/L with 73% neutrophils, 14% lymphocytes, and 12% monocytes. Hemoglobin was 11.8 g/dL and platelet count 292,000/L. Chemistry panel and liver function tests were unremarkable. Erythrocyte sedimentation rate (ESR) was 71 mm/hour (range, 010). Urinalysis was negative for protein and red blood cells. Chest x‐ray did not illustrate any abnormalities. Computed tomography (CT) of the lumbar spine revealed a small posterior disc bulge at L4‐5 and L5‐S1.
The moderate leukocytosis with neutrophilic predominance and monocytosis raises concern for a systemic inflammatory process; the elevated ESR further supports this. Monocytosis can be seen in a number of infectious, autoimmune, and malignant conditions. Tuberculosis, brucellosis, bacterial endocarditis, syphilis, infectious mononucleosis, and viral illnesses are among the infections typically characterized by monocytosis. Autoimmune illnesses, such as systemic lupus erythematosus and RA can also have similar presentations. The patient does not have any features of an underlying malignancy, such as weight loss or night sweats; however, if the autoimmune and infectious evaluations are negative, Hodgkin's disease and certain leukemias should be considered. There is no evidence of osteomyelitis on the spine CT, which decreases the possibility of (but does not exclude) infectious or rheumatologic conditions of the spine. I would suggest a comprehensive laboratory evaluation for the discussed infectious and rheumatologic disorders.
The patient's back pain was controlled with antiinflammatory medications overnight. Due to the patient's stable condition and lack of a diagnosis, empiric antibiotics were not initiated. An extensive workup was sent, including antistreptolysin O, polymerase chain reaction for Chlamydia, Neisseria gonorrhoeae, EBV, and parvovirus B19 DNA, serologies for Coccidioides immunoglobulin G (IgG) and IgM, urinary antigen for Histoplasma, HIV enzyme‐linked immunosorbent assay (ELISA) and Western blot, serum angiotensin‐converting enzyme level, C‐reactive protein, rheumatoid factor, antinuclear antibody, and antidouble‐stranded DNA antibodies.
Without a clear diagnosis, I would recommend against treatment with empiric antibiotics. At this point, I agree with waiting for the results of the pending workup.
On hospital day 1, the patient developed severe acute left ankle pain. On examination, the joint was exquisitely tender with decreased range of motion. Arthrocentesis was promptly performed. The synovial fluid WBC count was 1370/L with a differential of 82% neutrophils and 18% monocytes. No crystals were identified and the bacterial Gram stain was negative. He was treated with antiinflammatory medications. Bacterial blood cultures, obtained from the day of admission, were negative.
The arthrocentesis reveals a polymorphonuclear‐predominant fluid; however, the WBC count in the fluid is only mildly elevated. While the elevated monocyte count could again be consistent with viral arthropathies or juvenile RA, there is currently no systemic evidence of either illness. It is important to await the results of the final cultures, but the low WBC count and negative Gram stain decrease the probability of a septic joint. Empiric antibiotics to cover Gram‐positive organisms and gonococci would not be unreasonable, pending joint fluid culture results. The monocytosis could also be consistent with a fungal arthritis.
On hospital day 2, the results of the rheumatologic and infectious evaluation were negative with the exception of C‐reactive protein, which was 11.8 mg/dL (normal, <0.8), antinuclear antibody titer of 1:160 (normal, <1:40), Coccidioides IgM enzyme immunoassay (EIA) 0.710 (negative, <0.150), and Coccidioides tube‐precipitin (TP) immunodiffusion (ID) antibody‐positive. Coccidioides IgG EIA was negative.
The serologic tests are consistent with primary coccidioidomycosis. This is often a challenging diagnosis due to the nonspecific signs and symptoms, such as cough, fever, myalgias, and fatigue. Since screening EIAs are sensitive but not specific, concern for coccidioidomycosis or abnormal EIA results should prompt confirmatory testing with complement fixation titers (CF) and TP ID. Treatment with fluconazole should be initiated. Since the patient does not have central nervous system (CNS) symptoms, I would not recommend lumbar puncture at this point. However, a bone scan should be done for assessment of the back pain.
The patient was diagnosed with primary coccidioidomycosis infection with immune‐complexmediated arthritis and EN. A bone scan was negative. The patient was treated with fluconazole and discharged with 3 months of therapy. At follow‐up clinic visits after completion of therapy, his symptoms had resolved and his titers had normalized.
Discussion
The diagnosis of coccidioidomycosis is often challenging due to its protean manifestations. Four clinical syndromes are commonly seen: (1) acute pneumonia, (2) chronic progressive pneumonia, (3) pulmonary cavities and nodules, and (4) extrapulmonary disease involving the skin, lymph nodes, bones, joints, and meninges. The most common clinical manifestation, acute pneumonia, may be indistinguishable from other causes of community‐acquired pneumonia (CAP). In a study of CAP in Arizona, 29% of cases were positive for coccidioidal infection through serologic evaluation.1 Features suggestive of coccidioidal infection include fatigue, severe headache, and pleuritic chest pain. Adenopathy in the hilar or paratracheal regions can be seen in 25% of infections.2 Chronic progressive pneumonia refers to infections in which symptoms, including cough, hemoptysis, and weight loss, persist for longer than 3 months. Pulmonary nodules and cavities are residual manifestations of primary pulmonary infection and occur in 2% to 8% of cases. Extrapulmonary disease develops in less than 5% of immunocompetent patients with primary pulmonary infection, with higher prevalence in patients of African American and Filipino decent. Immunocompromised patients are at increased risk for extrapulmonary infection. The most serious site of extrapulmonary disease is the meninges. Coccidioidal meningitis carries nearly 100% mortality rate if left untreated. The presentation is variable with up to 75% of cases reporting headache. While coccidioidal pneumonia also frequently presents with headache, symptoms including altered mental status, focal neurological deficits, and persistent or progressive headache are more suggestive of meningeal disease.3
Patients with any presentation of coccidioidomycosis can display immune‐mediated manifestations such as EN, arthralgias (desert rheumatism), and in some cases mild conjunctivitis.4 It is hypothesized that these findings occur due to a hypersensitivity reaction to coccidioidomycosis.4 EN is an inflammatory process of the subcutaneous fat, which presents as tender and erythematous nodules typically on the lower extremities. EN is not a disease entity or site of metastatic infection, but a response to underlying illness. Its recognition should trigger a search for the primary etiology, as guided by the patient's history and clinical presentation. The differential diagnosis for EN is broad and includes rheumatologic, infectious, medication‐related, inflammatory, and idiopathic processes (Table 1). Coccidioidomycosis should be strongly considered based on geographical location, with the vast majority of cases seen in southern California, Arizona, Nevada, New Mexico, and Texas. While the pathophysiology of EN has not been completely elucidated, the lesions may reflect a vigorous immune response conferring a protective advantage. Interestingly, a study of pregnant women with coccidioidomycosis revealed a decreased incidence of disseminated disease in patients with EN.5, 6
Rheumatologic/autoimmune |
Systemic lupus erythematosus |
Wegener's granulomatosis |
Sarcoidosis |
Infectious |
Streptococcus pyogenes causing pharyngitis (most common) |
Borrelia burgdorferi |
Mycoplasma pneumoniae |
Bartonella henselae |
Shigella |
Campylobacter jejuni |
Salmonella |
Yersinia enterocolitica |
Chlamydia |
Brucella |
Escherichia coli |
Treponema pallidum |
Mycobacterium leprae |
Neisseria gonorrhoeae |
Mycobacterium tuberculosis |
Human immunodeficiency virus |
Epstein‐Barr virus |
Cytomegalovirus |
Influenza |
Varicella Zoster virus |
Coccidioides immitis |
Histoplasma capsulatum |
Blastomyces dermatitidis |
Dermatophytic fungal infections (rare) |
Gastrointestinal |
Ulcerative colitis |
Crohn's disease |
Celiac disease |
Behcet's disease |
Medications |
Oral contraceptives |
Proton pump inhibitors |
Sulfonamides |
Leukotriene modifiers (montelukast) |
Hepatitis B vaccine |
Isoretinoin |
Miscellaneous |
Hodgkins lymphoma |
Sweet's syndrome |
Coccidioidomycosis is also associated with immune‐mediated arthralgias and arthritis. These manifestations occur in up to one‐third of patients with concomitant EN. Arthritis may be monoarticular or polyarticular, often affecting large joints such as the knees or ankles. It is important to note that septic arthritis can also occur and should be differentiated from rheumatism by joint aspiration.
The diagnosis of coccidioidomycosis can be made by serologic testing, direct isolation of the organism on culture, or visualization on tissue biopsy. Of these methods, serologic testing is most commonly utilized. The 2007 Infectious Disease Society of America (IDSA) and American Thoracic Society guidelines recommend diagnostic testing in hospitalized patients with CAP who reside in or have recently traveled (within 2 weeks) to endemic areas.7 There are multiple approaches to serologic diagnosis based on identification of IgM or IgG antibodies to various coccidioidal antigens. During the early phase of infection, TP ID and EIA can be utilized to detect IgM antibodies. While EIA testing has 92% sensitivity, it has high rates of false‐positive results, and therefore confirmatory testing with ID is recommended. ID has variable sensitivity, but 90% of patients will test positive by 3 weeks of infection.8 During the later phase of the infection, IgG antibodies are detected either quantitatively by CF or qualitatively by ID and EIA. CF can provide information on the severity of illness and prognosis based on titer levels, as well as serving as a marker for response to treatment.2 Positive titers greater than 1:32 suggest disseminated disease. In addition, CF titer in the cerebrospinal fluid is the test of choice in diagnosis of coccidioidal meningitis. An evaluation for disseminated disease should be initiated if the patient has any risk factors or clinically concerning symptoms for bone or CNS involvement. This evaluation includes a bone scan and lumbar puncture. All patients should be assessed for immunocompromised status.
The management of coccidioidomycosis is based on the extent of infection, the severity of illness, and the immune status of the patient. In 95% of cases of uncomplicated pulmonary disease in an immunocompetent host, the symptoms will resolve without treatment with antifungal agents.9 The decision to treat uncomplicated pulmonary disease is based on severity of illness. While there is no consensus recommendation, commonly used indicators for treatment include persistent fever, age >55 years, symptoms greater than 2 months, hilar adenopathy, diffuse pulmonary infiltrates, weight loss, and inability to work.9 In patients with chronic progressive pneumonia or extrapulmonary involvement, treatment with antifungal medications should be initiated. While fluconazole remains the preferred treatment in coccidioidal pneumonia and meningitis, amphotericin B preparations should be considered for diffuse coccidioidal pneumonia and disseminated disease, including refractory meningitis.9 The use of newer azoles, particularly posaconazole, has been studied in a limited number of patients with refractory coccidioidomycosis with improvement in symptoms.10 Frequent follow‐up visits are recommended to detect progression of disease or to document resolution, with improving symptoms and decreasing titers. Duration of therapy in uncomplicated cases should be at least 3 months. Treatment of extrapulmonary disease can span years, and in the case of meningitis lifetime treatment is recommended given the high rate of relapse.
While the patient and the clinicians were aching for a diagnosis after the initial negative evaluation, recognition of the immunologic manifestations of coccidioidomycosis was essential in this case. Coccidioidomycosis should be considered in patients presenting with EN, regardless of presence of concurrent pulmonary symptoms; particularly in patients living in or with recent travel to endemic areas. Furthermore, the severity of symptoms can guide the decision and duration of treatment.
Teaching Points
-
Coccidioidomycosis has 4 main clinical presentations: (1) acute pneumonia, (2) chronic progressive pneumonia, (3) pulmonary cavities and nodules, and (4) extrapulmonary disease.
-
Independent of pulmonary symptoms, coccidioidomycosis can present with immune‐mediated manifestations, such as EN and arthritis.
-
The diagnosis of coccidioidomycosis often relies on serologic testing for early and late infection.
-
Treatment of coccidioidomycosis is based on risk factors and severity of symptoms. High‐risk and symptomatic patients can be treated with fluconazole or amphotericin B.
The approach to clinical conundrums by an expert clinician is revealed through presentation of an actual patient's case in an approach typical of morning report. Similar to patient care, sequential pieces of information are provided to the clinician who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring the patient and the discussant.
- Coccidioidomycosis as a common cause of community‐acquired pneumonia.Emerg Infect Dis.2006;12:958–962. , , , et al.
- Coccidioidomycosis.Mayo Clin Proc.2008;83:343–349. , .
- Coccidioidal meningitis.Clin Infect Dis.2006;42:103–107. , .
- Coccidioidomycosis: host response and vaccine development.Clin Microbiol Rev.2004;17:804–839. , .
- Erythema nodosum in pregnant patients with coccidioidomycosis.Clin Infect Dis.1998;27:1201–1203. , , .
- Protective effects of erythema nodosum in coccidioidomycosis.Lancet.1999;353:168. .
- Infectious Disease Society of America/American Thoracic Society consensus guidelines on management of community acquired pneumonia in adults.Clin Infect Dis.2007;44:S27–S72 , , , et al.
- Laboratory aspects in the diagnosis of coccidioidomycosis.Ann N Y Acad Sci.2007;1111:301–314. .
- Coccidioidomycosis.Clin Infect Dis.2005;41:1217–1223. , , , et al.
- Refractory coccidioidomycosis treated with posaconazole.Clin Infect Dis.2005;40:1770–1776. , , , , .
A 23‐year‐old Caucasian man presented to an outpatient clinic with a sore throat and associated subjective fevers. His evaluation included a negative rapid streptococcus test; nevertheless, he was empirically treated with amoxicillin. The following day, he experienced increasing sore throat and presented to the emergency department (ED). He was treated with prednisone and morphine sulfate and discharged home with azithromycin.
Initial considerations in a healthy young man who presents with fever and pharyngitis should focus on common infectious etiologies. Viral illnesses are the most frequent causes of sore throat and fever. These often manifest as mononucleosis‐like illnesses and include Epstein‐Barr virus (EBV) and cytomegalovirus (CMV). In this age group, it is also critical to consider sexually transmitted diseases (STDs) such as gonorrhea, human immunodeficiency virus (HIV), herpes simplex virus, and syphilis. Consideration of streptococcal pharyngitis is important. Since the rapid streptococcal antigen test is neither sensitive nor specific, confirmation of infection should be based on clinical findings and a culture of the pharynx for group A Streptococcus. Other common etiologies of fever and pharyngitis include acute or chronic sinusitis with postnasal drainage. Due to the progressive nature of the sore throat, there should be an evaluation for difficulty swallowing, problems phonating, or neck discomfort, any of which would be concerning for a retropharyngeal abscess. Additional history should be obtained with focus on sexual history, previous STDs, recent sick contacts, and other supporting signs and symptoms of viral illnesses.
Eight days after the initial onset of symptoms, the patient developed acute low back pain. The back pain was midline, severe, and constant around the lumbar spine. There was no saddle anesthesia, bowel or bladder dysfunction, or weakness or numbness in the extremities. He also noted swelling of the left fourth metacarpophalangeal joint and an erythematous rash on his right knee and anterior tibial region of the right leg. He continued to experience subjective fevers, sore throat, and swollen neck glands. Due to the severity and discomfort of symptoms, the patient returned to the ED.
With no history of trauma, the subsequent development of acute low back pain may be related to the patient's sore throat and fever. Monoarticular arthritis with contralateral skin lesions should raise suspicion for a systemic process, particularly infection or a rheumatologic syndrome. Infectious etiologies would include rheumatic fever, endocarditis with septic emboli, and osteomyelitis. Rheumatologic causes, such as ankylosing spondylitis and juvenile rheumatoid arthritis (RA), are also possibilities. The infectious evaluation should include an assessment of a history of intravenous drug use (IVDU) and underlying valvular disorders, which will increase the risk for endocarditis and therefore septic emboli. Acute HIV infection can be seen as early as 1 to 2 weeks postexposure and should be considered as well. Appropriate testing would include both conventional HIV antibody tests and HIV viral load assay. Lastly, in considering the patient's symptoms, obtaining his travel history to identify risk for Lyme disease would also be appropriate.
The patient did not report any further positive findings on review of systems. He did not have any significant past medical history and did not take any chronic medications. He had no sick contacts. He rarely drank alcohol and denied IVDU and sexual activity over the past year. He was previously involved in monogamous relationships with women. His last HIV test, 1 year prior, was negative. He did not have any history of STDs. He was a graduate student in computer science and lived in southern California. He had recently traveled to central California and France for 2 weeks, staying in larger cities. He had not been hiking during that time. His family history was significant for hypertension.
The travel history is provocative for 3 diseases of the reticuloendothelial system with possible systemic manifestations. First, toxoplasmosis, which is endemic in France where rare or raw beef and lamb are frequently consumed. It may present as a mononucleosis‐like illness and rarely as atypical pneumonia. Second, tuberculosis, which is also endemic in France, especially in major cities. Although most commonly a self‐limited respiratory disease, it may disseminate with systemic symptoms. Third, primary coccidioidomycosis, which is prevalent in the central valleys of California. The climate and wind patterns lead to aerosolization of the spores and make this a common respiratory pathogen.
The physical exam should include a detailed evaluation of the eyes for uveitis and iritis, seen in some rheumatologic disorders. A pharyngeal exam with assessment for exudate can support streptococcal pharyngitis or diphtheria. Evaluation for lymphadenopathy, while nonspecific, would be important for streptococcal pharyngitis, rheumatic fever, and juvenile RA. Further characterizing the rash is essential in distinguishing viral exanthems from the fleeting salmon‐colored maculopapular rash of juvenile RA. Assessment for peripheral stigmata of endocarditis should be done. A thorough joint exam should evaluate evidence of inflammatory or infectious joint disease.
On physical exam, he was a thin man who appeared anxious but in no acute distress. His temperature was 36.7C, blood pressure 111/68 mm Hg, heart rate 83 beats/minute, respiratory rate 16 breaths/minute, and oxygen saturation 99% on room air. Erythema was noted in the posterior oropharynx with no tonsillar exudate. There were several subcentimeter, nontender, and mobile lymph nodes in the anterior cervical chain bilaterally. The cardiovascular exam revealed normal sinus rhythm with a 2/6 systolic murmur at the apex, without radiation. His lungs were clear to auscultation. Skin exam revealed 2 blanching erythematous, indurated, and tender lesions on the right pretibial region, 2‐cm and 4‐cm in diameter. Two other similar, but smaller, lesions were noted on the left upper extremity and left ankle. His lumbar spine was slightly tender to touch. A complete joint exam was normal, including the left fourth metacarpophalangeal joint. Neurological exam, including bilateral strength, sensation, reflexes, and gait, was unremarkable.
Younger patients are subject to social‐acceptance bias and can deny sexual activity on initial inquiry. An objective evaluation for STDs with serologic workup should still be pursued. The cervical lymphadenopathy and tonsillar erythema continue to suggest a viral illness. While the systolic murmur may be physiologic, subjective fevers, disseminated cutaneous lesions, and arthritis warrant evaluation for bacterial endocarditis with blood cultures and an echocardiogram.
On exam, there is no evidence of true joint involvement and this decreases the likelihood of rheumatologic conditions, such as ankylosing spondylitis and juvenile RA. However, the skin lesions are suspicious for erythema nodosum (EN), which should prompt a biopsy and an evaluation for infectious etiologies. Serologies should include evaluation of Chlamydia, Mycoplasma, Coccidioides, and Histoplasma. I would also examine the feet carefully for potential transcutaneous inoculation by microorganisms that can produce a rash similar to EN. For instance, penetrating skin trauma can lead to pseudomonal infection. Brucella (from ingesting unpasteurized milk or milk products), Bartonella (from the scratches of feline animals), and Francisella tularensis (from rabbit exposure) can also produce skin lesions that mimic EN. These are best distinguished through a detailed history, concomitant serologic workup, and biopsy. Other noninfectious etiologies of EN can include inflammatory bowel disease, Behcet's, and sarcoidosis; however, the patient does not currently report any symptoms supporting these diagnoses. In addition to the above evaluation, complete blood count with differential, liver function tests, creatinine, and urinalysis should be obtained.
The patient's white blood cell (WBC) count was 12,100/L with 73% neutrophils, 14% lymphocytes, and 12% monocytes. Hemoglobin was 11.8 g/dL and platelet count 292,000/L. Chemistry panel and liver function tests were unremarkable. Erythrocyte sedimentation rate (ESR) was 71 mm/hour (range, 010). Urinalysis was negative for protein and red blood cells. Chest x‐ray did not illustrate any abnormalities. Computed tomography (CT) of the lumbar spine revealed a small posterior disc bulge at L4‐5 and L5‐S1.
The moderate leukocytosis with neutrophilic predominance and monocytosis raises concern for a systemic inflammatory process; the elevated ESR further supports this. Monocytosis can be seen in a number of infectious, autoimmune, and malignant conditions. Tuberculosis, brucellosis, bacterial endocarditis, syphilis, infectious mononucleosis, and viral illnesses are among the infections typically characterized by monocytosis. Autoimmune illnesses, such as systemic lupus erythematosus and RA can also have similar presentations. The patient does not have any features of an underlying malignancy, such as weight loss or night sweats; however, if the autoimmune and infectious evaluations are negative, Hodgkin's disease and certain leukemias should be considered. There is no evidence of osteomyelitis on the spine CT, which decreases the possibility of (but does not exclude) infectious or rheumatologic conditions of the spine. I would suggest a comprehensive laboratory evaluation for the discussed infectious and rheumatologic disorders.
The patient's back pain was controlled with antiinflammatory medications overnight. Due to the patient's stable condition and lack of a diagnosis, empiric antibiotics were not initiated. An extensive workup was sent, including antistreptolysin O, polymerase chain reaction for Chlamydia, Neisseria gonorrhoeae, EBV, and parvovirus B19 DNA, serologies for Coccidioides immunoglobulin G (IgG) and IgM, urinary antigen for Histoplasma, HIV enzyme‐linked immunosorbent assay (ELISA) and Western blot, serum angiotensin‐converting enzyme level, C‐reactive protein, rheumatoid factor, antinuclear antibody, and antidouble‐stranded DNA antibodies.
Without a clear diagnosis, I would recommend against treatment with empiric antibiotics. At this point, I agree with waiting for the results of the pending workup.
On hospital day 1, the patient developed severe acute left ankle pain. On examination, the joint was exquisitely tender with decreased range of motion. Arthrocentesis was promptly performed. The synovial fluid WBC count was 1370/L with a differential of 82% neutrophils and 18% monocytes. No crystals were identified and the bacterial Gram stain was negative. He was treated with antiinflammatory medications. Bacterial blood cultures, obtained from the day of admission, were negative.
The arthrocentesis reveals a polymorphonuclear‐predominant fluid; however, the WBC count in the fluid is only mildly elevated. While the elevated monocyte count could again be consistent with viral arthropathies or juvenile RA, there is currently no systemic evidence of either illness. It is important to await the results of the final cultures, but the low WBC count and negative Gram stain decrease the probability of a septic joint. Empiric antibiotics to cover Gram‐positive organisms and gonococci would not be unreasonable, pending joint fluid culture results. The monocytosis could also be consistent with a fungal arthritis.
On hospital day 2, the results of the rheumatologic and infectious evaluation were negative with the exception of C‐reactive protein, which was 11.8 mg/dL (normal, <0.8), antinuclear antibody titer of 1:160 (normal, <1:40), Coccidioides IgM enzyme immunoassay (EIA) 0.710 (negative, <0.150), and Coccidioides tube‐precipitin (TP) immunodiffusion (ID) antibody‐positive. Coccidioides IgG EIA was negative.
The serologic tests are consistent with primary coccidioidomycosis. This is often a challenging diagnosis due to the nonspecific signs and symptoms, such as cough, fever, myalgias, and fatigue. Since screening EIAs are sensitive but not specific, concern for coccidioidomycosis or abnormal EIA results should prompt confirmatory testing with complement fixation titers (CF) and TP ID. Treatment with fluconazole should be initiated. Since the patient does not have central nervous system (CNS) symptoms, I would not recommend lumbar puncture at this point. However, a bone scan should be done for assessment of the back pain.
The patient was diagnosed with primary coccidioidomycosis infection with immune‐complexmediated arthritis and EN. A bone scan was negative. The patient was treated with fluconazole and discharged with 3 months of therapy. At follow‐up clinic visits after completion of therapy, his symptoms had resolved and his titers had normalized.
Discussion
The diagnosis of coccidioidomycosis is often challenging due to its protean manifestations. Four clinical syndromes are commonly seen: (1) acute pneumonia, (2) chronic progressive pneumonia, (3) pulmonary cavities and nodules, and (4) extrapulmonary disease involving the skin, lymph nodes, bones, joints, and meninges. The most common clinical manifestation, acute pneumonia, may be indistinguishable from other causes of community‐acquired pneumonia (CAP). In a study of CAP in Arizona, 29% of cases were positive for coccidioidal infection through serologic evaluation.1 Features suggestive of coccidioidal infection include fatigue, severe headache, and pleuritic chest pain. Adenopathy in the hilar or paratracheal regions can be seen in 25% of infections.2 Chronic progressive pneumonia refers to infections in which symptoms, including cough, hemoptysis, and weight loss, persist for longer than 3 months. Pulmonary nodules and cavities are residual manifestations of primary pulmonary infection and occur in 2% to 8% of cases. Extrapulmonary disease develops in less than 5% of immunocompetent patients with primary pulmonary infection, with higher prevalence in patients of African American and Filipino decent. Immunocompromised patients are at increased risk for extrapulmonary infection. The most serious site of extrapulmonary disease is the meninges. Coccidioidal meningitis carries nearly 100% mortality rate if left untreated. The presentation is variable with up to 75% of cases reporting headache. While coccidioidal pneumonia also frequently presents with headache, symptoms including altered mental status, focal neurological deficits, and persistent or progressive headache are more suggestive of meningeal disease.3
Patients with any presentation of coccidioidomycosis can display immune‐mediated manifestations such as EN, arthralgias (desert rheumatism), and in some cases mild conjunctivitis.4 It is hypothesized that these findings occur due to a hypersensitivity reaction to coccidioidomycosis.4 EN is an inflammatory process of the subcutaneous fat, which presents as tender and erythematous nodules typically on the lower extremities. EN is not a disease entity or site of metastatic infection, but a response to underlying illness. Its recognition should trigger a search for the primary etiology, as guided by the patient's history and clinical presentation. The differential diagnosis for EN is broad and includes rheumatologic, infectious, medication‐related, inflammatory, and idiopathic processes (Table 1). Coccidioidomycosis should be strongly considered based on geographical location, with the vast majority of cases seen in southern California, Arizona, Nevada, New Mexico, and Texas. While the pathophysiology of EN has not been completely elucidated, the lesions may reflect a vigorous immune response conferring a protective advantage. Interestingly, a study of pregnant women with coccidioidomycosis revealed a decreased incidence of disseminated disease in patients with EN.5, 6
Rheumatologic/autoimmune |
Systemic lupus erythematosus |
Wegener's granulomatosis |
Sarcoidosis |
Infectious |
Streptococcus pyogenes causing pharyngitis (most common) |
Borrelia burgdorferi |
Mycoplasma pneumoniae |
Bartonella henselae |
Shigella |
Campylobacter jejuni |
Salmonella |
Yersinia enterocolitica |
Chlamydia |
Brucella |
Escherichia coli |
Treponema pallidum |
Mycobacterium leprae |
Neisseria gonorrhoeae |
Mycobacterium tuberculosis |
Human immunodeficiency virus |
Epstein‐Barr virus |
Cytomegalovirus |
Influenza |
Varicella Zoster virus |
Coccidioides immitis |
Histoplasma capsulatum |
Blastomyces dermatitidis |
Dermatophytic fungal infections (rare) |
Gastrointestinal |
Ulcerative colitis |
Crohn's disease |
Celiac disease |
Behcet's disease |
Medications |
Oral contraceptives |
Proton pump inhibitors |
Sulfonamides |
Leukotriene modifiers (montelukast) |
Hepatitis B vaccine |
Isoretinoin |
Miscellaneous |
Hodgkins lymphoma |
Sweet's syndrome |
Coccidioidomycosis is also associated with immune‐mediated arthralgias and arthritis. These manifestations occur in up to one‐third of patients with concomitant EN. Arthritis may be monoarticular or polyarticular, often affecting large joints such as the knees or ankles. It is important to note that septic arthritis can also occur and should be differentiated from rheumatism by joint aspiration.
The diagnosis of coccidioidomycosis can be made by serologic testing, direct isolation of the organism on culture, or visualization on tissue biopsy. Of these methods, serologic testing is most commonly utilized. The 2007 Infectious Disease Society of America (IDSA) and American Thoracic Society guidelines recommend diagnostic testing in hospitalized patients with CAP who reside in or have recently traveled (within 2 weeks) to endemic areas.7 There are multiple approaches to serologic diagnosis based on identification of IgM or IgG antibodies to various coccidioidal antigens. During the early phase of infection, TP ID and EIA can be utilized to detect IgM antibodies. While EIA testing has 92% sensitivity, it has high rates of false‐positive results, and therefore confirmatory testing with ID is recommended. ID has variable sensitivity, but 90% of patients will test positive by 3 weeks of infection.8 During the later phase of the infection, IgG antibodies are detected either quantitatively by CF or qualitatively by ID and EIA. CF can provide information on the severity of illness and prognosis based on titer levels, as well as serving as a marker for response to treatment.2 Positive titers greater than 1:32 suggest disseminated disease. In addition, CF titer in the cerebrospinal fluid is the test of choice in diagnosis of coccidioidal meningitis. An evaluation for disseminated disease should be initiated if the patient has any risk factors or clinically concerning symptoms for bone or CNS involvement. This evaluation includes a bone scan and lumbar puncture. All patients should be assessed for immunocompromised status.
The management of coccidioidomycosis is based on the extent of infection, the severity of illness, and the immune status of the patient. In 95% of cases of uncomplicated pulmonary disease in an immunocompetent host, the symptoms will resolve without treatment with antifungal agents.9 The decision to treat uncomplicated pulmonary disease is based on severity of illness. While there is no consensus recommendation, commonly used indicators for treatment include persistent fever, age >55 years, symptoms greater than 2 months, hilar adenopathy, diffuse pulmonary infiltrates, weight loss, and inability to work.9 In patients with chronic progressive pneumonia or extrapulmonary involvement, treatment with antifungal medications should be initiated. While fluconazole remains the preferred treatment in coccidioidal pneumonia and meningitis, amphotericin B preparations should be considered for diffuse coccidioidal pneumonia and disseminated disease, including refractory meningitis.9 The use of newer azoles, particularly posaconazole, has been studied in a limited number of patients with refractory coccidioidomycosis with improvement in symptoms.10 Frequent follow‐up visits are recommended to detect progression of disease or to document resolution, with improving symptoms and decreasing titers. Duration of therapy in uncomplicated cases should be at least 3 months. Treatment of extrapulmonary disease can span years, and in the case of meningitis lifetime treatment is recommended given the high rate of relapse.
While the patient and the clinicians were aching for a diagnosis after the initial negative evaluation, recognition of the immunologic manifestations of coccidioidomycosis was essential in this case. Coccidioidomycosis should be considered in patients presenting with EN, regardless of presence of concurrent pulmonary symptoms; particularly in patients living in or with recent travel to endemic areas. Furthermore, the severity of symptoms can guide the decision and duration of treatment.
Teaching Points
-
Coccidioidomycosis has 4 main clinical presentations: (1) acute pneumonia, (2) chronic progressive pneumonia, (3) pulmonary cavities and nodules, and (4) extrapulmonary disease.
-
Independent of pulmonary symptoms, coccidioidomycosis can present with immune‐mediated manifestations, such as EN and arthritis.
-
The diagnosis of coccidioidomycosis often relies on serologic testing for early and late infection.
-
Treatment of coccidioidomycosis is based on risk factors and severity of symptoms. High‐risk and symptomatic patients can be treated with fluconazole or amphotericin B.
The approach to clinical conundrums by an expert clinician is revealed through presentation of an actual patient's case in an approach typical of morning report. Similar to patient care, sequential pieces of information are provided to the clinician who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring the patient and the discussant.
A 23‐year‐old Caucasian man presented to an outpatient clinic with a sore throat and associated subjective fevers. His evaluation included a negative rapid streptococcus test; nevertheless, he was empirically treated with amoxicillin. The following day, he experienced increasing sore throat and presented to the emergency department (ED). He was treated with prednisone and morphine sulfate and discharged home with azithromycin.
Initial considerations in a healthy young man who presents with fever and pharyngitis should focus on common infectious etiologies. Viral illnesses are the most frequent causes of sore throat and fever. These often manifest as mononucleosis‐like illnesses and include Epstein‐Barr virus (EBV) and cytomegalovirus (CMV). In this age group, it is also critical to consider sexually transmitted diseases (STDs) such as gonorrhea, human immunodeficiency virus (HIV), herpes simplex virus, and syphilis. Consideration of streptococcal pharyngitis is important. Since the rapid streptococcal antigen test is neither sensitive nor specific, confirmation of infection should be based on clinical findings and a culture of the pharynx for group A Streptococcus. Other common etiologies of fever and pharyngitis include acute or chronic sinusitis with postnasal drainage. Due to the progressive nature of the sore throat, there should be an evaluation for difficulty swallowing, problems phonating, or neck discomfort, any of which would be concerning for a retropharyngeal abscess. Additional history should be obtained with focus on sexual history, previous STDs, recent sick contacts, and other supporting signs and symptoms of viral illnesses.
Eight days after the initial onset of symptoms, the patient developed acute low back pain. The back pain was midline, severe, and constant around the lumbar spine. There was no saddle anesthesia, bowel or bladder dysfunction, or weakness or numbness in the extremities. He also noted swelling of the left fourth metacarpophalangeal joint and an erythematous rash on his right knee and anterior tibial region of the right leg. He continued to experience subjective fevers, sore throat, and swollen neck glands. Due to the severity and discomfort of symptoms, the patient returned to the ED.
With no history of trauma, the subsequent development of acute low back pain may be related to the patient's sore throat and fever. Monoarticular arthritis with contralateral skin lesions should raise suspicion for a systemic process, particularly infection or a rheumatologic syndrome. Infectious etiologies would include rheumatic fever, endocarditis with septic emboli, and osteomyelitis. Rheumatologic causes, such as ankylosing spondylitis and juvenile rheumatoid arthritis (RA), are also possibilities. The infectious evaluation should include an assessment of a history of intravenous drug use (IVDU) and underlying valvular disorders, which will increase the risk for endocarditis and therefore septic emboli. Acute HIV infection can be seen as early as 1 to 2 weeks postexposure and should be considered as well. Appropriate testing would include both conventional HIV antibody tests and HIV viral load assay. Lastly, in considering the patient's symptoms, obtaining his travel history to identify risk for Lyme disease would also be appropriate.
The patient did not report any further positive findings on review of systems. He did not have any significant past medical history and did not take any chronic medications. He had no sick contacts. He rarely drank alcohol and denied IVDU and sexual activity over the past year. He was previously involved in monogamous relationships with women. His last HIV test, 1 year prior, was negative. He did not have any history of STDs. He was a graduate student in computer science and lived in southern California. He had recently traveled to central California and France for 2 weeks, staying in larger cities. He had not been hiking during that time. His family history was significant for hypertension.
The travel history is provocative for 3 diseases of the reticuloendothelial system with possible systemic manifestations. First, toxoplasmosis, which is endemic in France where rare or raw beef and lamb are frequently consumed. It may present as a mononucleosis‐like illness and rarely as atypical pneumonia. Second, tuberculosis, which is also endemic in France, especially in major cities. Although most commonly a self‐limited respiratory disease, it may disseminate with systemic symptoms. Third, primary coccidioidomycosis, which is prevalent in the central valleys of California. The climate and wind patterns lead to aerosolization of the spores and make this a common respiratory pathogen.
The physical exam should include a detailed evaluation of the eyes for uveitis and iritis, seen in some rheumatologic disorders. A pharyngeal exam with assessment for exudate can support streptococcal pharyngitis or diphtheria. Evaluation for lymphadenopathy, while nonspecific, would be important for streptococcal pharyngitis, rheumatic fever, and juvenile RA. Further characterizing the rash is essential in distinguishing viral exanthems from the fleeting salmon‐colored maculopapular rash of juvenile RA. Assessment for peripheral stigmata of endocarditis should be done. A thorough joint exam should evaluate evidence of inflammatory or infectious joint disease.
On physical exam, he was a thin man who appeared anxious but in no acute distress. His temperature was 36.7C, blood pressure 111/68 mm Hg, heart rate 83 beats/minute, respiratory rate 16 breaths/minute, and oxygen saturation 99% on room air. Erythema was noted in the posterior oropharynx with no tonsillar exudate. There were several subcentimeter, nontender, and mobile lymph nodes in the anterior cervical chain bilaterally. The cardiovascular exam revealed normal sinus rhythm with a 2/6 systolic murmur at the apex, without radiation. His lungs were clear to auscultation. Skin exam revealed 2 blanching erythematous, indurated, and tender lesions on the right pretibial region, 2‐cm and 4‐cm in diameter. Two other similar, but smaller, lesions were noted on the left upper extremity and left ankle. His lumbar spine was slightly tender to touch. A complete joint exam was normal, including the left fourth metacarpophalangeal joint. Neurological exam, including bilateral strength, sensation, reflexes, and gait, was unremarkable.
Younger patients are subject to social‐acceptance bias and can deny sexual activity on initial inquiry. An objective evaluation for STDs with serologic workup should still be pursued. The cervical lymphadenopathy and tonsillar erythema continue to suggest a viral illness. While the systolic murmur may be physiologic, subjective fevers, disseminated cutaneous lesions, and arthritis warrant evaluation for bacterial endocarditis with blood cultures and an echocardiogram.
On exam, there is no evidence of true joint involvement and this decreases the likelihood of rheumatologic conditions, such as ankylosing spondylitis and juvenile RA. However, the skin lesions are suspicious for erythema nodosum (EN), which should prompt a biopsy and an evaluation for infectious etiologies. Serologies should include evaluation of Chlamydia, Mycoplasma, Coccidioides, and Histoplasma. I would also examine the feet carefully for potential transcutaneous inoculation by microorganisms that can produce a rash similar to EN. For instance, penetrating skin trauma can lead to pseudomonal infection. Brucella (from ingesting unpasteurized milk or milk products), Bartonella (from the scratches of feline animals), and Francisella tularensis (from rabbit exposure) can also produce skin lesions that mimic EN. These are best distinguished through a detailed history, concomitant serologic workup, and biopsy. Other noninfectious etiologies of EN can include inflammatory bowel disease, Behcet's, and sarcoidosis; however, the patient does not currently report any symptoms supporting these diagnoses. In addition to the above evaluation, complete blood count with differential, liver function tests, creatinine, and urinalysis should be obtained.
The patient's white blood cell (WBC) count was 12,100/L with 73% neutrophils, 14% lymphocytes, and 12% monocytes. Hemoglobin was 11.8 g/dL and platelet count 292,000/L. Chemistry panel and liver function tests were unremarkable. Erythrocyte sedimentation rate (ESR) was 71 mm/hour (range, 010). Urinalysis was negative for protein and red blood cells. Chest x‐ray did not illustrate any abnormalities. Computed tomography (CT) of the lumbar spine revealed a small posterior disc bulge at L4‐5 and L5‐S1.
The moderate leukocytosis with neutrophilic predominance and monocytosis raises concern for a systemic inflammatory process; the elevated ESR further supports this. Monocytosis can be seen in a number of infectious, autoimmune, and malignant conditions. Tuberculosis, brucellosis, bacterial endocarditis, syphilis, infectious mononucleosis, and viral illnesses are among the infections typically characterized by monocytosis. Autoimmune illnesses, such as systemic lupus erythematosus and RA can also have similar presentations. The patient does not have any features of an underlying malignancy, such as weight loss or night sweats; however, if the autoimmune and infectious evaluations are negative, Hodgkin's disease and certain leukemias should be considered. There is no evidence of osteomyelitis on the spine CT, which decreases the possibility of (but does not exclude) infectious or rheumatologic conditions of the spine. I would suggest a comprehensive laboratory evaluation for the discussed infectious and rheumatologic disorders.
The patient's back pain was controlled with antiinflammatory medications overnight. Due to the patient's stable condition and lack of a diagnosis, empiric antibiotics were not initiated. An extensive workup was sent, including antistreptolysin O, polymerase chain reaction for Chlamydia, Neisseria gonorrhoeae, EBV, and parvovirus B19 DNA, serologies for Coccidioides immunoglobulin G (IgG) and IgM, urinary antigen for Histoplasma, HIV enzyme‐linked immunosorbent assay (ELISA) and Western blot, serum angiotensin‐converting enzyme level, C‐reactive protein, rheumatoid factor, antinuclear antibody, and antidouble‐stranded DNA antibodies.
Without a clear diagnosis, I would recommend against treatment with empiric antibiotics. At this point, I agree with waiting for the results of the pending workup.
On hospital day 1, the patient developed severe acute left ankle pain. On examination, the joint was exquisitely tender with decreased range of motion. Arthrocentesis was promptly performed. The synovial fluid WBC count was 1370/L with a differential of 82% neutrophils and 18% monocytes. No crystals were identified and the bacterial Gram stain was negative. He was treated with antiinflammatory medications. Bacterial blood cultures, obtained from the day of admission, were negative.
The arthrocentesis reveals a polymorphonuclear‐predominant fluid; however, the WBC count in the fluid is only mildly elevated. While the elevated monocyte count could again be consistent with viral arthropathies or juvenile RA, there is currently no systemic evidence of either illness. It is important to await the results of the final cultures, but the low WBC count and negative Gram stain decrease the probability of a septic joint. Empiric antibiotics to cover Gram‐positive organisms and gonococci would not be unreasonable, pending joint fluid culture results. The monocytosis could also be consistent with a fungal arthritis.
On hospital day 2, the results of the rheumatologic and infectious evaluation were negative with the exception of C‐reactive protein, which was 11.8 mg/dL (normal, <0.8), antinuclear antibody titer of 1:160 (normal, <1:40), Coccidioides IgM enzyme immunoassay (EIA) 0.710 (negative, <0.150), and Coccidioides tube‐precipitin (TP) immunodiffusion (ID) antibody‐positive. Coccidioides IgG EIA was negative.
The serologic tests are consistent with primary coccidioidomycosis. This is often a challenging diagnosis due to the nonspecific signs and symptoms, such as cough, fever, myalgias, and fatigue. Since screening EIAs are sensitive but not specific, concern for coccidioidomycosis or abnormal EIA results should prompt confirmatory testing with complement fixation titers (CF) and TP ID. Treatment with fluconazole should be initiated. Since the patient does not have central nervous system (CNS) symptoms, I would not recommend lumbar puncture at this point. However, a bone scan should be done for assessment of the back pain.
The patient was diagnosed with primary coccidioidomycosis infection with immune‐complexmediated arthritis and EN. A bone scan was negative. The patient was treated with fluconazole and discharged with 3 months of therapy. At follow‐up clinic visits after completion of therapy, his symptoms had resolved and his titers had normalized.
Discussion
The diagnosis of coccidioidomycosis is often challenging due to its protean manifestations. Four clinical syndromes are commonly seen: (1) acute pneumonia, (2) chronic progressive pneumonia, (3) pulmonary cavities and nodules, and (4) extrapulmonary disease involving the skin, lymph nodes, bones, joints, and meninges. The most common clinical manifestation, acute pneumonia, may be indistinguishable from other causes of community‐acquired pneumonia (CAP). In a study of CAP in Arizona, 29% of cases were positive for coccidioidal infection through serologic evaluation.1 Features suggestive of coccidioidal infection include fatigue, severe headache, and pleuritic chest pain. Adenopathy in the hilar or paratracheal regions can be seen in 25% of infections.2 Chronic progressive pneumonia refers to infections in which symptoms, including cough, hemoptysis, and weight loss, persist for longer than 3 months. Pulmonary nodules and cavities are residual manifestations of primary pulmonary infection and occur in 2% to 8% of cases. Extrapulmonary disease develops in less than 5% of immunocompetent patients with primary pulmonary infection, with higher prevalence in patients of African American and Filipino decent. Immunocompromised patients are at increased risk for extrapulmonary infection. The most serious site of extrapulmonary disease is the meninges. Coccidioidal meningitis carries nearly 100% mortality rate if left untreated. The presentation is variable with up to 75% of cases reporting headache. While coccidioidal pneumonia also frequently presents with headache, symptoms including altered mental status, focal neurological deficits, and persistent or progressive headache are more suggestive of meningeal disease.3
Patients with any presentation of coccidioidomycosis can display immune‐mediated manifestations such as EN, arthralgias (desert rheumatism), and in some cases mild conjunctivitis.4 It is hypothesized that these findings occur due to a hypersensitivity reaction to coccidioidomycosis.4 EN is an inflammatory process of the subcutaneous fat, which presents as tender and erythematous nodules typically on the lower extremities. EN is not a disease entity or site of metastatic infection, but a response to underlying illness. Its recognition should trigger a search for the primary etiology, as guided by the patient's history and clinical presentation. The differential diagnosis for EN is broad and includes rheumatologic, infectious, medication‐related, inflammatory, and idiopathic processes (Table 1). Coccidioidomycosis should be strongly considered based on geographical location, with the vast majority of cases seen in southern California, Arizona, Nevada, New Mexico, and Texas. While the pathophysiology of EN has not been completely elucidated, the lesions may reflect a vigorous immune response conferring a protective advantage. Interestingly, a study of pregnant women with coccidioidomycosis revealed a decreased incidence of disseminated disease in patients with EN.5, 6
Rheumatologic/autoimmune |
Systemic lupus erythematosus |
Wegener's granulomatosis |
Sarcoidosis |
Infectious |
Streptococcus pyogenes causing pharyngitis (most common) |
Borrelia burgdorferi |
Mycoplasma pneumoniae |
Bartonella henselae |
Shigella |
Campylobacter jejuni |
Salmonella |
Yersinia enterocolitica |
Chlamydia |
Brucella |
Escherichia coli |
Treponema pallidum |
Mycobacterium leprae |
Neisseria gonorrhoeae |
Mycobacterium tuberculosis |
Human immunodeficiency virus |
Epstein‐Barr virus |
Cytomegalovirus |
Influenza |
Varicella Zoster virus |
Coccidioides immitis |
Histoplasma capsulatum |
Blastomyces dermatitidis |
Dermatophytic fungal infections (rare) |
Gastrointestinal |
Ulcerative colitis |
Crohn's disease |
Celiac disease |
Behcet's disease |
Medications |
Oral contraceptives |
Proton pump inhibitors |
Sulfonamides |
Leukotriene modifiers (montelukast) |
Hepatitis B vaccine |
Isoretinoin |
Miscellaneous |
Hodgkins lymphoma |
Sweet's syndrome |
Coccidioidomycosis is also associated with immune‐mediated arthralgias and arthritis. These manifestations occur in up to one‐third of patients with concomitant EN. Arthritis may be monoarticular or polyarticular, often affecting large joints such as the knees or ankles. It is important to note that septic arthritis can also occur and should be differentiated from rheumatism by joint aspiration.
The diagnosis of coccidioidomycosis can be made by serologic testing, direct isolation of the organism on culture, or visualization on tissue biopsy. Of these methods, serologic testing is most commonly utilized. The 2007 Infectious Disease Society of America (IDSA) and American Thoracic Society guidelines recommend diagnostic testing in hospitalized patients with CAP who reside in or have recently traveled (within 2 weeks) to endemic areas.7 There are multiple approaches to serologic diagnosis based on identification of IgM or IgG antibodies to various coccidioidal antigens. During the early phase of infection, TP ID and EIA can be utilized to detect IgM antibodies. While EIA testing has 92% sensitivity, it has high rates of false‐positive results, and therefore confirmatory testing with ID is recommended. ID has variable sensitivity, but 90% of patients will test positive by 3 weeks of infection.8 During the later phase of the infection, IgG antibodies are detected either quantitatively by CF or qualitatively by ID and EIA. CF can provide information on the severity of illness and prognosis based on titer levels, as well as serving as a marker for response to treatment.2 Positive titers greater than 1:32 suggest disseminated disease. In addition, CF titer in the cerebrospinal fluid is the test of choice in diagnosis of coccidioidal meningitis. An evaluation for disseminated disease should be initiated if the patient has any risk factors or clinically concerning symptoms for bone or CNS involvement. This evaluation includes a bone scan and lumbar puncture. All patients should be assessed for immunocompromised status.
The management of coccidioidomycosis is based on the extent of infection, the severity of illness, and the immune status of the patient. In 95% of cases of uncomplicated pulmonary disease in an immunocompetent host, the symptoms will resolve without treatment with antifungal agents.9 The decision to treat uncomplicated pulmonary disease is based on severity of illness. While there is no consensus recommendation, commonly used indicators for treatment include persistent fever, age >55 years, symptoms greater than 2 months, hilar adenopathy, diffuse pulmonary infiltrates, weight loss, and inability to work.9 In patients with chronic progressive pneumonia or extrapulmonary involvement, treatment with antifungal medications should be initiated. While fluconazole remains the preferred treatment in coccidioidal pneumonia and meningitis, amphotericin B preparations should be considered for diffuse coccidioidal pneumonia and disseminated disease, including refractory meningitis.9 The use of newer azoles, particularly posaconazole, has been studied in a limited number of patients with refractory coccidioidomycosis with improvement in symptoms.10 Frequent follow‐up visits are recommended to detect progression of disease or to document resolution, with improving symptoms and decreasing titers. Duration of therapy in uncomplicated cases should be at least 3 months. Treatment of extrapulmonary disease can span years, and in the case of meningitis lifetime treatment is recommended given the high rate of relapse.
While the patient and the clinicians were aching for a diagnosis after the initial negative evaluation, recognition of the immunologic manifestations of coccidioidomycosis was essential in this case. Coccidioidomycosis should be considered in patients presenting with EN, regardless of presence of concurrent pulmonary symptoms; particularly in patients living in or with recent travel to endemic areas. Furthermore, the severity of symptoms can guide the decision and duration of treatment.
Teaching Points
-
Coccidioidomycosis has 4 main clinical presentations: (1) acute pneumonia, (2) chronic progressive pneumonia, (3) pulmonary cavities and nodules, and (4) extrapulmonary disease.
-
Independent of pulmonary symptoms, coccidioidomycosis can present with immune‐mediated manifestations, such as EN and arthritis.
-
The diagnosis of coccidioidomycosis often relies on serologic testing for early and late infection.
-
Treatment of coccidioidomycosis is based on risk factors and severity of symptoms. High‐risk and symptomatic patients can be treated with fluconazole or amphotericin B.
The approach to clinical conundrums by an expert clinician is revealed through presentation of an actual patient's case in an approach typical of morning report. Similar to patient care, sequential pieces of information are provided to the clinician who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring the patient and the discussant.
- Coccidioidomycosis as a common cause of community‐acquired pneumonia.Emerg Infect Dis.2006;12:958–962. , , , et al.
- Coccidioidomycosis.Mayo Clin Proc.2008;83:343–349. , .
- Coccidioidal meningitis.Clin Infect Dis.2006;42:103–107. , .
- Coccidioidomycosis: host response and vaccine development.Clin Microbiol Rev.2004;17:804–839. , .
- Erythema nodosum in pregnant patients with coccidioidomycosis.Clin Infect Dis.1998;27:1201–1203. , , .
- Protective effects of erythema nodosum in coccidioidomycosis.Lancet.1999;353:168. .
- Infectious Disease Society of America/American Thoracic Society consensus guidelines on management of community acquired pneumonia in adults.Clin Infect Dis.2007;44:S27–S72 , , , et al.
- Laboratory aspects in the diagnosis of coccidioidomycosis.Ann N Y Acad Sci.2007;1111:301–314. .
- Coccidioidomycosis.Clin Infect Dis.2005;41:1217–1223. , , , et al.
- Refractory coccidioidomycosis treated with posaconazole.Clin Infect Dis.2005;40:1770–1776. , , , , .
- Coccidioidomycosis as a common cause of community‐acquired pneumonia.Emerg Infect Dis.2006;12:958–962. , , , et al.
- Coccidioidomycosis.Mayo Clin Proc.2008;83:343–349. , .
- Coccidioidal meningitis.Clin Infect Dis.2006;42:103–107. , .
- Coccidioidomycosis: host response and vaccine development.Clin Microbiol Rev.2004;17:804–839. , .
- Erythema nodosum in pregnant patients with coccidioidomycosis.Clin Infect Dis.1998;27:1201–1203. , , .
- Protective effects of erythema nodosum in coccidioidomycosis.Lancet.1999;353:168. .
- Infectious Disease Society of America/American Thoracic Society consensus guidelines on management of community acquired pneumonia in adults.Clin Infect Dis.2007;44:S27–S72 , , , et al.
- Laboratory aspects in the diagnosis of coccidioidomycosis.Ann N Y Acad Sci.2007;1111:301–314. .
- Coccidioidomycosis.Clin Infect Dis.2005;41:1217–1223. , , , et al.
- Refractory coccidioidomycosis treated with posaconazole.Clin Infect Dis.2005;40:1770–1776. , , , , .